Cantex secures license to develop small molecule-drug for inflammatory lung diseases
pharmaphorum
FEBRUARY 24, 2022
It is currently the only oral small molecule RAGE inhibitor in human clinical trials. According to Cantex, azeliragon has previously been tested for Alzheimer’s disease and diabetic nephropathy, where the drug demonstrated high levels of safety in phase 3 clinical trials involving more than 2,000 patients.
Let's personalize your content